Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 88.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 88.00%, a 3.72% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 89.70%, a 2.18% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 91.00%, a 1.30% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 91.40%, a 0.98% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 91.50%, a 1.19% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 92.60%, a 5.83% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 87.50%, a 7.76% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 81.20%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 88.00% 10-Q · filed 2026-08-04 | 89.40% 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 89.70% 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 91.50% 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 91.00% 10-Q · filed 2025-11-05 | 91.50% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 91.40% 10-Q · filed 2026-08-04 | 91.60% 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | 91.70% 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | 92.60% 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | 92.20% 10-Q · filed 2025-11-05 | 92.70% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 92.30% 10-Q · filed 2025-08-07 | 92.70% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 93.10% 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | 87.50% 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | 91.70% 10-Q · filed 2024-11-07 | 86.40% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 86.40% 10-Q · filed 2024-08-08 | 85.00% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 84.10% 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 81.20% 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | 87.30% 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | 87.67% 8-K · filed 2023-12-21 | 80.50% 10-K · filed 2022-03-08 | |||
| 2020-12-31 | 80.40% 10-K · filed 2022-03-08 | ||||
| 2019-12-31 | 78.50% 10-K · filed 2021-03-03 | ||||
| 2018-12-31 | 78.40% 10-K · filed 2020-03-03 | ||||
| 2017-12-31 | 78.10% 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |